|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:EGLN3-TAB3 (FusionGDB2 ID:HG112399TG257397) |
Fusion Gene Summary for EGLN3-TAB3 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: EGLN3-TAB3 | Fusion gene ID: hg112399tg257397 | Hgene | Tgene | Gene symbol | EGLN3 | TAB3 | Gene ID | 112399 | 257397 |
| Gene name | egl-9 family hypoxia inducible factor 3 | TGF-beta activated kinase 1 (MAP3K7) binding protein 3 | |
| Synonyms | HIFP4H3|HIFPH3|PHD3 | MAP3K7IP3|NAP1 | |
| Cytomap | ('EGLN3')('TAB3') 14q13.1 | Xp21.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | egl nine homolog 3HIF-PH3HIF-prolyl hydroxylase 3HPH-1HPH-3egl nine-like protein 3 isoformhypoxia-inducible factor prolyl hydroxylase 3prolyl hydroxylase domain-containing protein 3 | TGF-beta-activated kinase 1 and MAP3K7-binding protein 3NF-kappa-B-activating protein 1NFkB activating protein 1TAB-3TAK1-binding protein 3TGF-beta activated kinase 1 and MAP3K7 binding protein 3TGF-beta-activated kinase 1-binding protein 3mitogen- | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q9H6Z9 | . | |
| Ensembl transtripts involved in fusion gene | ENST00000250457, ENST00000547327, ENST00000553215, ENST00000557521, | ||
| Fusion gene scores | * DoF score | 7 X 6 X 2=84 | 1 X 1 X 1=1 |
| # samples | 7 | 1 | |
| ** MAII score | log2(7/84*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(1/1*10)=3.32192809488736 | |
| Context | PubMed: EGLN3 [Title/Abstract] AND TAB3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | EGLN3(34881613)-TAB3(30845559), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | EGLN3 | GO:0018126 | protein hydroxylation | 19584355 |
| Hgene | EGLN3 | GO:0018401 | peptidyl-proline hydroxylation to 4-hydroxy-L-proline | 11598268 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS5.0 | N/A | BI492282 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
Top |
Fusion Gene ORF analysis for EGLN3-TAB3 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-intron | ENST00000250457 | ENST00000288422 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000250457 | ENST00000378928 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000250457 | ENST00000378930 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000250457 | ENST00000378932 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000250457 | ENST00000378933 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000547327 | ENST00000288422 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000547327 | ENST00000378928 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000547327 | ENST00000378930 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000547327 | ENST00000378932 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000547327 | ENST00000378933 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000553215 | ENST00000288422 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000553215 | ENST00000378928 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000553215 | ENST00000378930 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000553215 | ENST00000378932 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000553215 | ENST00000378933 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000557521 | ENST00000288422 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000557521 | ENST00000378928 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000557521 | ENST00000378930 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000557521 | ENST00000378932 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| intron-intron | ENST00000557521 | ENST00000378933 | EGLN3 | chr14 | 34881613 | - | TAB3 | chrX | 30845559 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for EGLN3-TAB3 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for EGLN3-TAB3 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:34881613/:30845559) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| EGLN3 | . |
| FUNCTION: Prolyl hydroxylase that mediates hydroxylation of proline residues in target proteins, such as PKM, TELO2, ATF4 and HIF1A (PubMed:19584355, PubMed:21620138, PubMed:21483450, PubMed:22797300, PubMed:20978507, PubMed:21575608). Target proteins are preferentially recognized via a LXXLAP motif. Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins (PubMed:11595184, PubMed:12181324). Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A (PubMed:11595184, PubMed:12181324). Also hydroxylates HIF2A (PubMed:11595184, PubMed:12181324). Has a preference for the CODD site for both HIF1A and HIF2A (PubMed:11595184, PubMed:12181324). Hydroxylation on the NODD site by EGLN3 appears to require prior hydroxylation on the CODD site (PubMed:11595184, PubMed:12181324). Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex (PubMed:11595184, PubMed:12181324). Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes (PubMed:11595184, PubMed:12181324). ELGN3 is the most important isozyme in limiting physiological activation of HIFs (particularly HIF2A) in hypoxia. Also hydroxylates PKM in hypoxia, limiting glycolysis (PubMed:21620138, PubMed:21483450). Under normoxia, hydroxylates and regulates the stability of ADRB2 (PubMed:19584355). Regulator of cardiomyocyte and neuronal apoptosis. In cardiomyocytes, inhibits the anti-apoptotic effect of BCL2 by disrupting the BAX-BCL2 complex (PubMed:20849813). In neurons, has a NGF-induced proapoptotic effect, probably through regulating CASP3 activity (PubMed:16098468). Also essential for hypoxic regulation of neutrophilic inflammation (PubMed:21317538). Plays a crucial role in DNA damage response (DDR) by hydroxylating TELO2, promoting its interaction with ATR which is required for activation of the ATR/CHK1/p53 pathway (PubMed:22797300). Also mediates hydroxylation of ATF4, leading to decreased protein stability of ATF4 (Probable). {ECO:0000269|PubMed:11595184, ECO:0000269|PubMed:12181324, ECO:0000269|PubMed:16098468, ECO:0000269|PubMed:19584355, ECO:0000269|PubMed:20849813, ECO:0000269|PubMed:20978507, ECO:0000269|PubMed:21317538, ECO:0000269|PubMed:21483450, ECO:0000269|PubMed:21575608, ECO:0000269|PubMed:21620138, ECO:0000269|PubMed:22797300, ECO:0000305|PubMed:17684156}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for EGLN3-TAB3 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for EGLN3-TAB3 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for EGLN3-TAB3 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | EGLN3 | Q9H6Z9 | DB00126 | Ascorbic acid | Chaperone | Small molecule | Approved|Nutraceutical |
Top |
Related Diseases for EGLN3-TAB3 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | EGLN3 | C0023903 | Liver neoplasms | 1 | CTD_human |
| Hgene | EGLN3 | C0345904 | Malignant neoplasm of liver | 1 | CTD_human |
| Hgene | EGLN3 | C1527405 | Erythrocytosis | 1 | GENOMICS_ENGLAND |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies